Literature DB >> 21355904

Patients on injectable diacetylmorphine maintenance have low bone mass.

Kenneth M Dürsteler-MacFarland1, Roland Kowalewski, Nicole Bloch, Gerhard A Wiesbeck, Marius E Kraenzlin, Rudolf Stohler.   

Abstract

INTRODUCTION AND AIMS: Risk factors for osteoporosis are prevalent in chronic heroin users who often start using opiates in their late teens. This study was the first to evaluate bone mineral density (BMD) in relatively young heroin-dependent patients on injectable heroin maintenance. DESIGN AND METHODS: Using cross-sectional design, BMD was assessed in a convenience sample of 19 patients (mean age ± SD = 33.9 ± 5.4; 13 men) prescribed injectable diacetylmorphine for heroin dependence. BMD of the lumbar spine and proximal femur was measured by dual-energy X-ray absorptiometry. Substance use and menstrual history, psychopathology and risk factors for low BMD were assessed by questionnaire-based interviews.
RESULTS: According to World Health Organisation criteria almost three-quarters (74%) of the sample had osteopenia (n = 11) or osteoporosis (n = 3) at one or more sites of measurement. All patients showed multiple risk factors for bone loss, with pack-years of tobacco use and years of heroin use reaching marginally significant associations with spine Z-scores. Moreover, BMD Z-scores correlated significantly negatively with increasing age at all sites, indicating that the older the patient, the greater the BMD deviation from an age-controlled population. DISCUSSION AND
CONCLUSIONS: Prolonged heroin dependence appears to be associated with lower-than-normal bone mass already at early age and these individuals might be at greater risk for fracture with advancing age. The negative correlation of age-adjusted Z-scores with increasing age suggests factors other than age for low BMD in this population (e.g. smoking, heroin use). Prospective studies are warranted to determine the necessity for diagnostic and preventive measures.
© 2010 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21355904     DOI: 10.1111/j.1465-3362.2010.00242.x

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  7 in total

1.  Bisphosphonate treatment may reduce osteoporosis risk in female cancer patients with morphine use: a population-based nested case-control study.

Authors:  C W-S Lee; C-H Muo; J-A Liang; S-N Chang; Y-J Chang; C-H Kao
Journal:  Osteoporos Int       Date:  2013-03-08       Impact factor: 4.507

2.  Bone mineral density and its determinants in men with opioid dependence.

Authors:  Frank Gotthardt; Christine Huber; Clara Thierfelder; Leticia Grize; Marius Kraenzlin; Claude Scheidegger; Christian Meier
Journal:  J Bone Miner Metab       Date:  2016-01-08       Impact factor: 2.626

3.  Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain.

Authors:  Hong Zhang; Dominique M Lund; Haley A Ciccone; William D Staatz; Mohab M Ibrahim; Tally M Largent-Milnes; Herbert H Seltzman; Igor Spigelman; Todd W Vanderah
Journal:  Pain       Date:  2018-09       Impact factor: 7.926

4.  Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis.

Authors:  Aleksandra Janas; Joanna Folwarczna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-28       Impact factor: 3.000

5.  Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.

Authors:  Brittany L Forte; Lauren M Slosky; Hong Zhang; Moriah R Arnold; William D Staatz; Meredith Hay; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Pain       Date:  2016-12       Impact factor: 6.961

6.  Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.

Authors:  Ella T Nkhoma; Lisa Rosenblatt; Joel Myers; Angelina Villasis-Keever; John Coumbis
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

7.  Dichotomic effects of clinically used drugs on tumor growth, bone remodeling and pain management.

Authors:  David André Barrière; Élora Midavaine; Louis Doré-Savard; Karyn Kirby; Luc Tremblay; Jean-François Beaudoin; Nicolas Beaudet; Jean-Michel Longpré; Roger Lecomte; Martin Lepage; Philippe Sarret
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.